In the BioHarmony Drug Report Database

"Preview" Icon

Dapagliflozin

Farxiga, Edistride, Forxiga (dapagliflozin) is a small molecule pharmaceutical. Dapagliflozin was first approved as Farxiga on 2012-11-11. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 1 diabetes mellitus and type 2 diabetes mellitus. It is known to target sodium/glucose cotransporter 2 and sodium/glucose cotransporter 1. Farxiga’s patents are valid until 2040-03-09 (FDA).

 

Trade Name

 

Edistride, Forxiga
 

Common Name

 

dapagliflozin
 

ChEMBL ID

 

CHEMBL429910
 

Indication

 

type 1 diabetes mellitus, type 2 diabetes mellitus
 

Drug Class

 

Phlorozin derivatives, phenolic glycosides

Image (chem structure or protein)

Dapagliflozin structure rendering